A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2017
At a glance
- Drugs ASP 6294 (Primary) ; ASP 6294 (Primary)
- Indications Interstitial cystitis
- Focus Adverse reactions
- Sponsors Astellas Pharma Europe Ltd
- 09 Jan 2017 Status changed from active, no longer recruiting to completed.
- 19 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Feb 2016 New trial record